FNY Partners Fund’s TherapeuticsMD TXMD Stock Holding History

FNY Partners Fund’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-100	Closed	-$36K	–	1131
2017 Q1	$36K	Buy	+100	New	+$30.9K	﹤0.01%	812

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

FNY Partners Fund's TXMD Position: Q2 2017 in Review

FNY Partners Fund sold out of TherapeuticsMD (TXMD) in Q2 2017, closing a stake of 100 shares — an estimated $36K sold.

FNY Partners Fund first reported a position in TXMD in Q1 2017 and held it in 1 quarter. The position peaked at $36K in Q1 2017. 117 funds tracked by Wall St. Rank hold TXMD as of Q2 2017.

FNY Partners Fund reported no remaining TherapeuticsMD position as of Q2 2017 after selling out during the quarter.
FNY Partners Fund sold 100 TherapeuticsMD shares in Q2 2017, an estimated $36K.
FNY Partners Fund first reported a position in TherapeuticsMD in Q1 2017 and held it in 1 quarter.
FNY Partners Fund's TherapeuticsMD position peaked at $36K in Q1 2017.
117 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.